Argenta, Porsolt To Provide CNS and Pain Services

Argenta Discovery and Porsolt have entered into an alliance to provide CNS and pain drug discovery services. The collaboration allows the two companies to undertake fully integrated CNS and pain-focused drug discovery programs for their clients, from hit identification to development candidate nomination.

Dr. Christopher Ashton, chief executive officer of Argenta said, “Argenta has undertaken many successful medicinal chemistry-driven CNS and pain contract drug discovery research projects, but we have been looking at ways of enhancing our capabilities in these important therapeutic areas. Argenta has partnered with Porsolt to provide clients with dedicated access to specialist CNS and pain models and expertise, offered by a world leader in the field. We have several ongoing contract research programs in these therapeutic areas and a number of projects in the pipeline, which are likely to benefit from Porsolt’s support and know-how. This alliance will enable Argenta to offer an even better integrated drug discovery service in the future. We are looking forward to working with Porsolt.”

Dr. Mark Duxon, chief executive officer of Porsolt added, “Porsolt is delighted to be entering into a partnership with Argenta to deliver full lead optimization drug discovery on a contract research basis. Porsolt have recently announced a significant laboratory expansion in France and the Argenta partnership fits with our strategy of offering a diverse array of deal structure opportunities to suit the broad range of our clients’ needs. Indeed, our increased business flexibility is entirely complementary to our client-oriented scientific expertise. Porsolt has always sought to deliver quality scientific solutions tailored to client needs. In this respect, we believe we have found a like minded partner in Argenta.”